Advisory Board October 22, 2024

Amid financial challenges and a full board resignation, DNA testing company 23andMe is reportedly considering a sale, meaning the genetic data of more than 15 million people could end up under new ownership.

Data privacy and the FTC: Who is working to protect your data?

What a sale could mean for 23andMe’s genetic data

Over almost 20 years, 23andMe has built a large genetic database that includes a plethora of information about customers’ health predispositions and ancestral backgrounds.

Currently, the company’s privacy policies emphasize that each customer’s consent is required to share any genetic information, but those policies also state that customer information is a salable asset in the event of a merger or acquisition.

A spokesperson for 23andMe told...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Pharma / Biotech, Precision Medicine
Bringing genomics closer to patients: 3 takeaways from Henry Ford Health
Oncologist talks personalized medicine for pancreatic cancer
AI offers a step above genomic solutions
How Mayo Clinic is using real-world data to advance precision medicine
Aignostics Secures $34 Million Series B to Enhance Precision Medicine with AI

Share This Article